{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Kind&page=4",
    "query": {
      "intervention": "Kind",
      "page": 4
    },
    "page_size": 10
  },
  "pagination": {
    "page": 4,
    "page_size": 10,
    "total_count": 10453,
    "total_pages": 1046,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Kind&page=5&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Kind&page=3&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-28T15:07:38.164Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05589844",
      "title": "A Cytomegalovirus-Directed Vaccine (CMV-alphaDC1) for Preventing Cytomegalovirus Infection or Reactivation in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cytomegaloviral Infection",
        "Hematopoietic and Lymphoid System Neoplasm"
      ],
      "interventions": [
        {
          "name": "Allogeneic Hematopoietic Stem Cell Transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "CMV pp65 Peptide-loaded Alpha-type-1 Polarized Dendritic Cell Vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "BIOLOGICAL"
      ],
      "sponsor": "Roswell Park Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2023-03",
      "completion_date": "2025-11-16",
      "has_results": false,
      "last_update_posted_date": "2023-04-27",
      "last_synced_at": "2026-10-28T15:07:38.164Z",
      "location_count": 1,
      "location_summary": "Buffalo, New York",
      "locations": [
        {
          "city": "Buffalo",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05589844"
    },
    {
      "nct_id": "NCT07160244",
      "title": "BEATRIX: A Study to Learn About a Group B Streptococcus Vaccine in Healthy Pregnant Women and Their Babies",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Multivalent Group B streptococcus vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Infanrix hexa",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Prevenar 20",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pediarix",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Prevnar 20",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Infanrix",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "1 Day",
        "maximum_age": "49 Years",
        "sex": "ALL",
        "summary": "1 Day to 49 Years"
      },
      "enrollment_count": 6000,
      "start_date": "2025-08-25",
      "completion_date": "2029-03-02",
      "has_results": false,
      "last_update_posted_date": "2026-10-27",
      "last_synced_at": "2026-10-28T15:07:38.164Z",
      "location_count": 119,
      "location_summary": "Birmingham, Alabama • Dothan, Alabama • Mobile, Alabama + 54 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Dothan",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07160244"
    },
    {
      "nct_id": "NCT00046709",
      "title": "Marijuana for Cancer Pain",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Neoplasms"
      ],
      "interventions": [
        {
          "name": "Smoked Marijuana",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Center for Medicinal Cannabis Research",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 16,
      "start_date": "2002-09",
      "completion_date": "2004-10",
      "has_results": false,
      "last_update_posted_date": "2013-10-10",
      "last_synced_at": "2026-10-28T15:07:38.164Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00046709"
    },
    {
      "nct_id": "NCT04532034",
      "title": "Facilitating Engagement in Evidence-Based Treatment for Early Psychosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Psychotic Disorders"
      ],
      "interventions": [
        {
          "name": "Peer-Delivered Decision Support Intervention",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Temple University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "30 Years",
        "sex": "ALL",
        "summary": "18 Years to 30 Years"
      },
      "enrollment_count": 12,
      "start_date": "2020-09-01",
      "completion_date": "2023-03-31",
      "has_results": true,
      "last_update_posted_date": "2024-04-17",
      "last_synced_at": "2026-10-28T15:07:38.164Z",
      "location_count": 3,
      "location_summary": "Broomall, Pennsylvania • Danville, Pennsylvania • Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Broomall",
          "state": "Pennsylvania"
        },
        {
          "city": "Danville",
          "state": "Pennsylvania"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04532034"
    },
    {
      "nct_id": "NCT01469104",
      "title": "Metabolic Response to 3-day Fast Versus Carbohydrate-free Diet in Type 2 Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Type 2 Diabetes"
      ],
      "interventions": [
        {
          "name": "3 day fast",
          "type": "OTHER"
        },
        {
          "name": "3 day CHO-free diet",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Minneapolis Veterans Affairs Medical Center",
      "sponsor_class": "FED",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "45 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "45 Years to 75 Years"
      },
      "enrollment_count": 7,
      "start_date": "2009-08",
      "completion_date": "2010-06",
      "has_results": false,
      "last_update_posted_date": "2011-11-10",
      "last_synced_at": "2026-10-28T15:07:38.164Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01469104"
    },
    {
      "nct_id": "NCT04391049",
      "title": "Testing the Addition of the Anti-cancer Viral Therapy Telomelysin™ to Chemoradiation for Patients With Advanced Esophageal Cancer and Are Not Candidates for Surgery",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Esophageal Adenocarcinoma",
        "Advanced Gastroesophageal Junction Adenocarcinoma",
        "Clinical Stage II Esophageal Adenocarcinoma AJCC v8",
        "Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8",
        "Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8",
        "Clinical Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8",
        "Clinical Stage IIB Esophageal Adenocarcinoma AJCC v8",
        "Clinical Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8",
        "Clinical Stage III Esophageal Adenocarcinoma AJCC v8",
        "Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8",
        "Pathologic Stage II Esophageal Adenocarcinoma AJCC v8",
        "Pathologic Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8",
        "Pathologic Stage IIA Esophageal Adenocarcinoma AJCC v8",
        "Pathologic Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8",
        "Pathologic Stage IIB Esophageal Adenocarcinoma AJCC v8",
        "Pathologic Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8",
        "Pathologic Stage III Esophageal Adenocarcinoma AJCC v8",
        "Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8",
        "Pathologic Stage IIIA Esophageal Adenocarcinoma AJCC v8",
        "Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8",
        "Pathologic Stage IIIB Esophageal Adenocarcinoma AJCC v8",
        "Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8",
        "Postneoadjuvant Therapy Stage II Esophageal Adenocarcinoma AJCC v8",
        "Postneoadjuvant Therapy Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8",
        "Postneoadjuvant Therapy Stage III Esophageal Adenocarcinoma AJCC v8",
        "Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8",
        "Postneoadjuvant Therapy Stage IIIA Esophageal Adenocarcinoma AJCC v8",
        "Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8",
        "Postneoadjuvant Therapy Stage IIIB Esophageal Adenocarcinoma AJCC v8",
        "Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8",
        "Unresectable Gastroesophageal Junction Adenocarcinoma",
        "Squamous Cell Carcinoma",
        "Squamous Cell Cancer"
      ],
      "interventions": [
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Radiation Therapy",
          "type": "RADIATION"
        },
        {
          "name": "Telomerase-specific Type 5 Adenovirus OBP-301",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION",
        "BIOLOGICAL"
      ],
      "sponsor": "NRG Oncology",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 16,
      "start_date": "2021-12-02",
      "completion_date": "2029-10-06",
      "has_results": true,
      "last_update_posted_date": "2026-10-01",
      "last_synced_at": "2026-10-28T15:07:38.164Z",
      "location_count": 17,
      "location_summary": "Duarte, California • South Pasadena, California • Upland, California + 14 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "South Pasadena",
          "state": "California"
        },
        {
          "city": "Upland",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Fairway",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04391049"
    },
    {
      "nct_id": "NCT02372955",
      "title": "Mechanistic Study of the Systolic Blood Pressure Lowering Effect of Dapagliflozin in Type 2 Diabetes",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Diabetes Mellitus Type 2"
      ],
      "interventions": [
        {
          "name": "dapagliflozin",
          "type": "DRUG"
        },
        {
          "name": "glimpiride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gulf Regional Research & Educational Services, LLC",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "21 Years and older"
      },
      "enrollment_count": 21,
      "start_date": "2015-02",
      "completion_date": "2016-12",
      "has_results": false,
      "last_update_posted_date": "2015-02-26",
      "last_synced_at": "2026-10-28T15:07:38.164Z",
      "location_count": 1,
      "location_summary": "Metairie, Louisiana",
      "locations": [
        {
          "city": "Metairie",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02372955"
    },
    {
      "nct_id": "NCT00515099",
      "title": "Study of Antithymocyte Globulin for Treatment of New-onset T1DM",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "New-onset Type 1 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "Antithymocyte globulin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "35 Years",
        "sex": "ALL",
        "summary": "12 Years to 35 Years"
      },
      "enrollment_count": 58,
      "start_date": "2007-08",
      "completion_date": "2013-07",
      "has_results": true,
      "last_update_posted_date": "2017-05-11",
      "last_synced_at": "2026-10-28T15:07:38.164Z",
      "location_count": 9,
      "location_summary": "Los Angeles, California • Oakland, California • San Diego, California + 6 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00515099"
    },
    {
      "nct_id": "NCT02973087",
      "title": "rVWF IN PROPHYLAXIS",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Von Willebrand Disease"
      ],
      "interventions": [
        {
          "name": "von Willebrand factor (Recombinant)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Antihemophilic Factor (Recombinant)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Takeda",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 29,
      "start_date": "2017-11-16",
      "completion_date": "2020-07-06",
      "has_results": true,
      "last_update_posted_date": "2021-08-06",
      "last_synced_at": "2026-10-28T15:07:38.164Z",
      "location_count": 8,
      "location_summary": "Loveland, Colorado • Gainesville, Florida • Jacksonville, Florida + 5 more",
      "locations": [
        {
          "city": "Loveland",
          "state": "Colorado"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Peoria",
          "state": "Illinois"
        },
        {
          "city": "Aurora",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02973087"
    },
    {
      "nct_id": "NCT01201278",
      "title": "PK/PD Study of Intranasal Insulin in Type I Diabetes",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Type 1 Diabetes"
      ],
      "interventions": [
        {
          "name": "Insulin",
          "type": "DRUG"
        },
        {
          "name": "Insulin LISPRO",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hompesch, Marcus, M.D.",
      "sponsor_class": "INDIV",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 20,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2011-06-17",
      "last_synced_at": "2026-10-28T15:07:38.164Z",
      "location_count": 1,
      "location_summary": "Chula Vista, California",
      "locations": [
        {
          "city": "Chula Vista",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01201278"
    }
  ]
}